NCT05896969View on ClinicalTrials.gov

Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

February 23, 2024

Study Completion Date

February 23, 2024

Conditions
Elevated Low-Density Lipoprotein Cholesterol
Interventions
DRUG

SNK-396 - SAD cohort

A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.

DRUG

SNK-396 - MAD Cohort

Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.

Trial Locations (3)

3004

Nucleus Network Pty Ltd, Melbourne

4006

Nucleus Network Pty Ltd, Herston

5000

Cmax Clinical Research, Adelaide

Sponsors

Lead Sponsor

Syneos Health
All Listed Sponsors
collaborator

SynerK Pharmatech (Suzhou) Limited

UNKNOWN

lead

Syneos Health

OTHER

NCT05896969 - Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol | Biotech Hunter | Biotech Hunter